Physician profile
Anna H Williams
NPI 1083103782
$4,280.56
in general payments reported to CMS, 2019-2025
23 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $1,220 · 2023: $1,250 · 2024: $1,003 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.79 | 2021-2024 | |
| Glaxosmithkline, LLC. | $576.83 | 2022-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Amgen INC. | $438.02 | 2021-2024 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $394.69 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $326.99 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.71 | 2021-2024 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $295.24 | 2022-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $273.83 | 2021-2023 | |
| Exact Sciences Corporation | $212.35 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $141.79 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $67.52 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $58.90 | 2022-2023 | Livalo, Seglentis |
| Corcept Therapeutics | $56.05 | 2024-2025 | Korlym |
| Gilead Sciences, INC. | $46.93 | 2024 | |
| Novavax INC | $45.01 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.41 | 2023 | |
| Dexcom, INC. | $40.36 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $39.25 | 2021-2022 | |
| Abbott Laboratories | $34.77 | 2022 | |
| Corium, LLC | $27.73 | 2023 | Azstarys |
| Redhill Biopharma INC. | $27.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.97 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $15.82 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.